Literature DB >> 18034418

Manipulation of NK cytotoxicity by the IAP family member Livin.

Boaz Nachmias1, Sa'ar Mizrahi, Meital Elmalech, Itay Lazar, Yaqoub Ashhab, Roi Gazit, Gal Markel, Dina Ben-Yehuda, Ofer Mandelboim.   

Abstract

Natural killer (NK) cells are part of the innate immune system, capable of killing tumor and virally infected cells. NK cells induce apoptosis in the target cell by either granule- or receptor-mediated pathways. A set of inhibitory and activation ligands governs NK cell activation. As transformed cells often attempt to evade NK cell killing, up-regulation of a potential anti-apoptotic factor should provide a survival advantage. The inhibitor of apoptosis protein (IAP) family can inhibit apoptosis induced by a variety of stimuli. We have previously described a new IAP family member, termed Livin, which has two splice variants (alpha and beta) with differential anti-apoptotic activities. In this study, we explore the ability of Livin to inhibit NK cell-induced killing. We demonstrate that Livin beta moderately protects against NK cell killing whereas Livin alpha augments killing. We show that Livin beta inhibition in Jurkat cells is apparent upon concomitant activation of an inhibitory signal, suggesting that Livin augments an extrinsic inhibitory signal rather than functioning as an independent inhibitory mechanism. Finally, we demonstrate that detection of both Livin isoforms in melanoma cells correlates with a low killing rate. To date, this is the first evidence that directly demonstrates the ability of IAP to protect against NK cell-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034418     DOI: 10.1002/eji.200636600

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin.

Authors:  Itay Lazar; Barak Yaacov; Tamar Shiloach; Elad Eliahoo; Luna Kadouri; Michal Lotem; Riki Perlman; Zichria Zakay-Rones; Amos Panet; Dina Ben-Yehuda
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

2.  Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.

Authors:  Birgit Engesæter; Olav Engebraaten; Vivi Ann Flørenes; Gunhild Mari Mælandsmo
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

3.  Investigation and Validation of Molecular Characteristics of Endometrium in Recurrent Miscarriage and Unexplained Infertility from a Transcriptomic Perspective.

Authors:  Yuxin Ran; Jie He; Ruixin Chen; Yan Qin; Zheng Liu; Yunqian Zhou; Nanlin Yin; Hongbo Qi; Wei Zhou
Journal:  Int J Med Sci       Date:  2022-03-06       Impact factor: 3.738

4.  The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice.

Authors:  Michael Bobardt; Joseph Kuo; Udayan Chatterji; Norbert Wiedemann; Gregoire Vuagniaux; Philippe Gallay
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.